Release Date: 21-Jul-2024
Trilaciclib, developed by G1 Therapeutics, has made significant strides in cancer treatment as a novel CDK4/6 inhibitor. Administered intravenously before chemotherapy, it aims to reduce chemotherapy-induced myelosuppression.
The drug’s achievements began with its US FDA approval in February 2021 under the brand name Cosela for extensive-stage small cell lung cancer (ES-SCLC) patients. Its global expansion continued with China’s National Medical Products Administration (NMPA) granting conditional approval in July 2022 for the same indication.
A notable milestone was reached in October 2023 when the NMPA cleared Cosela’s new drug application to transition from conditional to regular approval in China. This progression from conditional to full approval underscores the drug’s demonstrated efficacy and safety profile in real-world use.
These regulatory successes highlight Trilaciclib’s potential to transform chemotherapy outcomes, particularly for ES-SCLC patients. The drug’s journey from conditional to full approval in China exemplifies its growing acceptance and importance in major global markets.
For More Information on Drug Trials in China Contact